Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.

Show more authors
+ 10
D J McGrail
P G Pilié
N U Rashid
L Voorwerk
M Slagter
M Kok
E Jonasch
M Khasraw
A B Heimberger
N T Ueno
R Ferrarotto
J T Chang
S-Y Lin

More about this publication

Annals of oncology : official journal of the European Society for Medical Oncology

Volume 32
Issue nr. 9
Pages 1194-1197
Publication date 01-09-2021

Full text links

Publisher website (DOI) 10.1016/j.annonc.2021.06.017
Europe PubMed Central 34166757
Pubmed 34166757

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.